CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

Hideki Muramatsu, Yoshiyuki Takahashi, Yoshie Shimoyama, Sayoko Doisaki, Nobuhiro Nishio, Yoshinori Ito, Asahito Hama, Akira Shimada, Hiroshi Yagasaki, Masafumi Ito, Seiji Kojima

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

Original languageEnglish
Pages (from-to)779-781
Number of pages3
JournalInternational journal of hematology
Volume93
Issue number6
DOIs
Publication statusPublished - Jun 2011

Keywords

  • Aplastic anemia
  • CD20
  • Epstein-Barr virus
  • Post-transplant lymphoproliferative disease
  • Rituximab
  • Unrelated bone marrow transplantation

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia'. Together they form a unique fingerprint.

Cite this